Missouri, Kansas and Idaho can press forward with their lawsuit to restrict access to the abortion drug mifepristone, a federal judge ruled Thursday, months after the US Supreme Court had rejected an earlier version of the legal challenge.

The three states argue that the FDA's approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.

Abortion policy could see more changes across the U.S. as President-elect Donald Trump begins his second term and state legislative sessions get rolling.

A Texas judge has allowed Idaho, Kansas, and Missouri to challenge federal rules on the abortion drug mifepristone. The states want stricter regulations, citing conflict with state abortion laws. The case continues despite a prior Supreme Court decision maintaining access to the drug.

After abortion opponents and doctors failed in their case to have the drug restricted — the Supreme Court ruled they lacked standing — Idaho, Kansas, and Missouri stepped in. Meanwhile, other states are making moves to protect reproductive rights.

A federal judge in Texas is allowing three other states to pursue a challenge seeking to restrict access to the abortion pill mifepristone nationwide.

The states of Idaho, Kansas and Missouri made the request in U.S. District Court in Amarillo, Texas. The only judge based there is Matthew Kacsmaryk, a nominee of former President Donald Trump who previously ruled in favor of a challenge to the pill’s approval.

Trump-appointed Judge Matthew Kacsmaryk ruled Thursday that Idaho, Kansas, and Missouri can pursue legal action to prohibit the FDA from allowing online prescriptions.

A Texas federal judge Thursday ruled Idaho, Kansas and Missouri can join a case challenging access to the abortion pill.

Three states will get to proceed with their challenge to the use of an abortion drug - after a ruling by a federal judge in Texas. Idaho, Kansas and Missouri want the FDA to block the drug mifepristone.

The states want the federal Food and Drug Administration to prohibit telehealth prescriptions for mifepristone and require that it be used only in the first seven weeks of pregnancy instead of the current limit of 10 weeks.